Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Clinical trial NCT03572400 · UNKNOWN

Trial details

NCT number: NCT03572400
Sponsor: Do-Youn Oh
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2018-11-29
Primary completion: 2024-12-31
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.